Compare · CAI vs ILMN
CAI vs ILMN
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 41.6x CAI ($971.9M).
- ILMN has been more active in the news (8 items in the past 4 weeks vs 3 for CAI).
- ILMN has more recent analyst coverage (25 ratings vs 16 for CAI).
- Company
- Caris Life Sciences Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $971.9M
- $40.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 3
- 8
- Recent ratings
- 16
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CAI
- Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
- Officer Denton John Russel sold $238,626 worth of shares (7,500 units at $31.82), decreasing direct ownership by 4% to 174,855 units (SEC Form 4)
- Officer Brille Brian J exercised 400,000 shares at a strike of $2.44 and sold $12,132,080 worth of shares (400,000 units at $30.33) (SEC Form 4)
- Caris Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- UBS initiated coverage on Caris Life Sciences with a new price target
- Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
- Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
- Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
- SEC Form 144 filed by Caris Life Sciences Inc.
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)